DVAHealthcare · Medical Care FacilitiesThe 7 Wall Street analysts covering DaVita, Inc. hold a median 12-month price target of $220 — +19.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 19 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DaVita, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (55): Analysts have, on balance, been cutting their forecasts.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DVA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.7% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | TD Cowen | Upgrade | Buy | $201 → $220 |
| 7 Aug 2026 | Truist Securities | Maintains | Hold | $250 → $215 |
| 5 Aug 2026 | Barclays | Maintains | Equal-Weight | $218 → $224 |
| 14 July 2026 | Truist Securities | Maintains | Hold | $205 → $250 |
| 14 July 2026 | Truist Securities | Maintains | Hold | — |
| 10 July 2026 | UBS | Maintains | Buy | $235 → $270 |
| 10 July 2026 | UBS | Maintains | Buy | — |
| 9 July 2026 | Barclays | Maintains | Equal-Weight | $194 → $218 |
| 9 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 11 May 2026 | TD Cowen | Maintains | Hold | — |
| 8 May 2026 | Barclays | Maintains | Equal-Weight | — |
| 8 May 2026 | Truist Securities | Maintains | Hold | — |
| 7 May 2026 | UBS | Maintains | Buy | — |
| 6 May 2026 | Deutsche Bank | Upgrade | Buy | — |
| 4 Feb 2026 | UBS | Maintains | Buy | — |
| 3 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 3 Nov 2025 | TD Cowen | Maintains | Hold | — |
| 30 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
| 9 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
| 10 Sept 2025 | B of A Securities | Maintains | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DVA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, DaVita, Inc. returned +41.2% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 45% of US stocks
Cheaper than 73% of US stocks
Cheaper than 9% of US stocks
Cheaper than 40% of US stocks
Higher than 39% of US stocks
Higher than 67% of US stocks
Higher than 38% of US stocks
Higher than 74% of US stocks
Higher than 62% of US stocks
Higher than 96% of US stocks
Higher than 86% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DaVita, Inc. has a market value of $11.8B and an enterprise value of $26.3B.
Revenue in the twelve months to 30 June 2026: $14.0B. The latest quarter grew 5.2% year on year.
Net income over the same four quarters: $1.2B, a 8.5% net margin.
Diluted earnings per share, trailing twelve months: $12.22.
Free cash flow in the twelve months to 30 June 2026: $1.6B.
DaVita, Inc. spent $1.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 15.6×; forward P/E: 10.7× — the forward figure prices analyst consensus estimates, not reported earnings.
DaVita, Inc. employs 78,000 people — $180K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DaVita, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
DaVita HealthCare (DVA) closed the most recent trading day at $193.86, advancing +1.55% from the previous trading session while the broader market declined.
Why it matters — A DVA watcher would note that the stock moved higher on a day when the market declined, reflecting positive relative performance for the company.
President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The White House says Trump has no knowledge of the trades, which span a wide range of sectors and dollar amounts.
Why it matters — This broad trading disclosure may interest DVA watchers as it indicates overlapping stock positions involving high-profile figures, though the report does not specifically mention DaVita.
Zacks notes that DaVita benefits from expanding value-based kidney care, improving dialysis volumes, and clinical innovation, while cautioning that payer-mix and regulatory risks persist. The report recommends retaining the stock for now without adding new positions or divesting.
Why it matters — DVA watchers would note the balance between operational growth drivers and ongoing payer-mix and regulatory headwinds that continue to shape the company's outlook.
Zacks reports that DaVita HealthCare (DVA) has declined 4.9% since its earnings report roughly 30 days ago. The article examines what may come next for the stock following that earnings release.
Why it matters — A DVA watcher would note the stock's post-earnings decline as a recent performance signal amid uncertainty over what direction the company may take next.
Zacks Investment Research reports that recent movements in the options market for DaVita (DVA) stock may warrant investor attention. The piece highlights unusual options activity without drawing definitive conclusions about the company's outlook.
Why it matters — Options-market activity can signal how sophisticated traders are positioning on DVA, so a DVA watcher would want to track whether these movements foreshadow changes in the stock.
The 7 Wall Street analysts covering DaVita, Inc. have a median 12-month price target of $220, with estimates ranging from $165 to $270. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering DaVita, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks DaVita, Inc. 90 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, DaVita, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +19.7% from the last close, and Ticker Nerd's factor model ranks DaVita, Inc. 90 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DaVita, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $270 over the next 12 months.
DaVita, Inc. returned +41.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease.
The most recent item we track (Zacks Investment Research, 16 Sept 2026): "DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors". DaVita HealthCare (DVA) closed the most recent trading day at $193.86, advancing +1.55% from the previous trading session while the broader market declined.
DaVita Inc. is a healthcare services company focused on kidney care, with its core business centered on outpatient dialysis for patients living with chronic kidney disease and end-stage renal disease. DaVita provides in-center hemodialysis, peritoneal dialysis, and home dialysis options, along with related clinical support and care coordination services. The company also operates integrated kidney care programs and offers ancillary services that support treatment management and patient care across the kidney health journey. With a large network of dialysis centers in the United States and international markets, DaVita plays a major role in delivering life-sustaining renal care and serving healthcare systems, insurers, and patients who require ongoing treatment.
CEO Mr. Javier J. Rodriguez · 78,000 employees · United States · https://www.davita.com
